Buy Trodelvy in India—Price & Availability

What is Trodelvy used for?

Trodelvy (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate. It links an antibody that targets the Trop-2 protein on cancer cells to a chemotherapy payload (the topoisomerase inhibitor SN-38), delivering treatment more directly to the tumour. It is approved for adults with:

• Metastatic triple-negative breast cancer (mTNBC) — unresectable, locally advanced, or metastatic disease in patients who have had two or more prior systemic therapies, at least one of them for metastatic disease.
• HR-positive, HER2-negative breast cancer — unresectable, locally advanced or metastatic disease (IHC 0, IHC 1+, or IHC 2+/ISH–) after endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:
The recommended dose is 10 mg/kg as an intravenous infusion once weekly on Days 1 and 8 of each 21-day cycle, continued until disease progression or unacceptable toxicity. Doses above 10 mg/kg are not recommended, and Trodelvy must be given only as an IV infusion — never as a push or bolus. The first infusion is given over 3 hours with observation; later infusions may be given over 1–2 hours if well tolerated. The treating oncologist always determines dosing.

Boxed warning: Trodelvy carries a boxed warning for severe or life-threatening neutropenia (very low white blood cells) and severe diarrhea. Blood counts are monitored, and treatment may be delayed or doses adjusted to manage these effects.

• Low white blood cell counts (neutropenia): increases infection risk; report fever, chills, or weakness promptly.
• Severe diarrhea: can cause dehydration; tell your doctor at the first sign so it can be managed early.
• Hypersensitivity and infusion reactions: patients are monitored during and after the infusion; pre-medication may be given.
• Nausea and vomiting: common; anti-nausea medicines are usually prescribed beforehand.
• Pregnancy and breastfeeding: Trodelvy can harm an unborn baby; effective contraception is advised, and breastfeeding is not recommended during and for a period after treatment.

Common side effects:
Frequently reported effects include hair loss, fatigue or weakness, low red blood cell count, constipation, rash, decreased appetite, and abdominal discomfort. This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Trodelvy through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
  Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Trodelvy is sourced and shipped under validated 2–8°C conditions to the patient or treating hospital.

Documents required to import Trodelvy:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports
• Government-issued patient ID proof
• An import permit, where applicable

How is the order confirmed? 

The order will be confirmed only after the receipt of:

• A valid prescription from a doctor.
• Import permit if applicable.

Is TRODELVY available in India?

TRODELVY (Sacituzumab govitecan-hziy injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) facilitates the import of cancer medicines under named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Trodelvy in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Gurgaon, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Trodelvy price in India.
• Finding Genuine and reliable sources from the USA, Canada,
• Europe, and Australia
• Ensuring 100% transparency.

TRODELVY can be made available to patients, doctors, and hospitals in Mumbai, Delhi, Bangalore, Gurgaon, Kolkata, Bhubaneswar, Pune, Hyderabad, Chennai, Kerala, Ahmedbad, Surat, Lucknow, Visakhapatnam, Jaipur, Patna, Nagpur, Indore, Noida, Jodhpur, Varanasi, Ghaziabad, Secunderabad, Bhopal, Agra, Chandigarh, Agartala, Kanpur, Guwahati, Imphal, Puducherry, Kohima, Ludhiana, Srinagar, Amritsar, Gorakhpur, Dehradun, Jammu, Hyderabad, Kochi, Coimbatore, Mysuru, Salem, Thiruvananthapuram, Vellore, Guntur, Tiruppur, Kolhapur, Goa, Namchi, Nashik, and various other regions in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of TRODELVY (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact us at WhatsApp: +91 98104 69557 | Toll-Free Number: 1800-1200-365 or write us at info@indianpharmanetwork.in for Trodelvy cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Because Trodelvy is not sold on the open market in India, there is no fixed MRP. The Trodelvy cost in India depends on a few factors at the time of import:

• The number of 180 mg / 200 mg vials required per cycle, which is based on the patient’s body weight and dosing schedule.
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote:
We provide a written quotation covering Trodelvy cost, logistics, and delivery timeline once a valid prescription is shared. Request your Trodelvy quote →

Trodelvy is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

Indian Pharma Network sources Trodelvy from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Trodelvy requires cold-chain handling at 2°C–8°C throughout transit, protected from light and never frozen. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Trodelvy can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:
Trodelvy first received US FDA approval on 22 April 2020 for metastatic triple-negative breast cancer, with later approvals for additional breast cancer indications. It is approved in several markets, including the United States, the European Union, Canada, Japan, China, and South Korea. As of the current publicly available information, Trodelvy is not commercially marketed in India, which is why the Named Patient route is used.